TY  - JOUR
AU  - Stetefeld, Henning R.
AU  - Schaal, Alexander
AU  - Scheibe, Franziska
AU  - Nichtweiß, Julia
AU  - Lehmann, Felix
AU  - Müller, Marcus
AU  - Gerner, Stefan T.
AU  - Huttner, Hagen B.
AU  - Luger, Sebastian
AU  - Fuhrer, Hannah
AU  - Bösel, Julian
AU  - Schönenberger, Silvia
AU  - Dimitriadis, Konstantinos
AU  - Neumann, Bernhard
AU  - Fuchs, Kornelius
AU  - Fink, Gereon R.
AU  - Malter, Michael P.
TI  - Isoflurane in (Super-) Refractory Status Epilepticus: A Multicenter Evaluation
JO  - Neurocritical care
VL  - 35
IS  - 3
SN  - 1541-6933
CY  - New York, NY
PB  - Springer
M1  - FZJ-2021-05955
SP  - 631 - 639
PY  - 2021
AB  - AbstractBackground: We aimed to determine the association between seizure termination and side effects of isoflurane forthe treatment of refractory status epilepticus (RSE) and super-refractory status epilepticus (SRSE) in neurointensivecare units (neuro-ICUs).Methods: This was a multicenter retrospective study of patients with RSE/SRSE treated with isoflurane for statusepilepticus termination admitted to the neuro-ICUs of nine German university centers during 2011–2018.Results: We identified 45 patients who received isoflurane for the treatment of RSE/SRSE. During isoflurane treat-ment, electroencephalograms showed no epileptiform discharges in 33 of 41 (80%) patients, and burst suppressionpattern was achieved in 29 of 41 patients (71%). RSE/SRSE was finally terminated after treatment with isoflurane in 23of 45 patients (51%) for the entire group and in 13 of 45 patients (29%) without additional therapy. Lengths of stay inthe hospital and in the neuro-ICU were significantly extended in cases of ongoing status epilepticus under isofluranetreatment (p = 0.01 for length of stay in the hospital, p = 0.049 for length in the neuro-ICU). During isoflurane treat-ment, side effects were reported in 40 of 45 patients (89%) and mainly included hypotension (n = 40, 89%) and/orinfection (n = 20, 44%). Whether side effects occurred did not affect the outcome at discharge. Of 22 patients withfollow-up magnetic resonance imaging, 2 patients (9%) showed progressive magnetic resonance imaging alterationsthat were considered to be potentially associated with RSE/SRSE itself or with isoflurane therapy.Conclusions: Isoflurane was associated with a good effect in stopping RSE/SRSE. Nevertheless, establishing remis-sion remained difficult. Side effects were common but without effect on the outcome at discharge.Keywords: Status epilepticus, Isoflurane, Epilepsy
LB  - PUB:(DE-HGF)16
C6  - pmid:34286464
UR  - <Go to ISI:>//WOS:000677824300005
DO  - DOI:10.1007/s12028-021-01250-z
UR  - https://juser.fz-juelich.de/record/904385
ER  -